Remicade

Remicade (also known as Infliximab) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-α) and is used to treat autoimmune diseases. It is produced by Janssen Biotech, which is owned by Johnson & Johnson.

Medical Uses

Remicade is used for the treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. It works by binding to TNF-α. TNF-α is a chemical messenger in the immune system and is also a key factor in the inflammatory process of autoimmune diseases.

Side Effects

Common side effects include infections (such as tuberculosis, sepsis, and fungal infections), infusion reactions, headache, stomach pain, and nausea. Serious side effects may include heart failure, a higher rate of serious infections, and an increased risk of cancer.

Pharmacology

Infliximab is a chimeric monoclonal antibody. It is composed of human constant and murine variable regions. Infliximab binds specifically to TNF-α and blocks its interaction with the p55 and p75 cell surface TNF receptors.

History

Remicade was approved for medical use in the United States in 1998, and in the European Union in 1999. It was the first TNF-α blocker to be approved.

See Also

• List of drugs: I
• List of monoclonal antibodies

Remicade Resources
Latest articles Most recent articles Ongoing trials	Wikipedia